BackEikon Therapeutics Common Stock Overview

Eikon Therapeutics Common Stock Accounts Payable

Track Eikon Therapeutics Common Stock's accounts payable ($6M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$6.00M

Peer trimmed avg / median

Loading

Eikon Therapeutics Common Stock Accounts Payable History

Loading

Eikon Therapeutics Common Stock vs. peers: Accounts Payable Comparison

Loading

Eikon Therapeutics Common Stock Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Eikon Therapeutics Common Stock (EIKN) FAQ

The latest accounts payable for EIKN is $6M as of March 2026. Investors often review this figure alongside Eikon Therapeutics Common Stock's historical trend and sector peers before judging valuation or financial health.

A accounts payable figure of $6M for EIKN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EIKN's accounts payable ($6M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Eikon Therapeutics Common Stock's accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.